Innovative Gene Therapy Delivered via Nasal Spray Targets Lungs and Airways

In a significant advancement in the field of gene therapy, researchers at Mass General Brigham have developed an innovative method to efficiently target the lungs and airways using a nasal spray. This new therapy utilizes a modified adeno-associated virus (AAV), known as AAV.CPP.16, which has shown superior capabilities in delivering therapeutic molecules directly to respiratory tissues.

Conventional gene therapy often faces challenges in delivering treatments to specific locations within the body. The newly engineered AAV.CPP.16, initially designed for targeting the central nervous system, demonstrated unexpected efficacy in lung cell targeting. This prompted further investigation into its potential for intranasal gene delivery.

In a series of preclinical studies, AAV.CPP.16 consistently outperformed previous AAV versions, such as AAV6 and AAV9, across various models including cell cultures, mouse models, and non-human primate studies. The research team successfully employed this advanced delivery system to administer gene therapy aimed at preventing scarring in pulmonary fibrosis, as well as to combat viral infections, including inhibiting the replication of the SARS-CoV-2 virus in COVID-19 mouse models.

FengFeng Bei, Ph.D., a senior author of the study, stated that while further research is necessary, the findings indicate a strong potential for AAV.CPP.16 as a viable delivery mechanism for targeting respiratory conditions.

This groundbreaking research is published in the journal Cell Reports Medicine, highlighting the promising implications of AAV.CPP.16 for future treatments of respiratory diseases.

As the research progresses, there is optimism surrounding the application of AAV.CPP.16 for a variety of respiratory ailments. The ability to deliver gene therapies through a non-invasive method like a nasal spray could revolutionize treatment protocols for conditions that currently require more invasive approaches.

With the ongoing development of this technology, healthcare professionals may soon have access to more effective therapeutic options for patients suffering from chronic respiratory diseases and viral infections.